Antinuclear Antibody Determination: The Present State of Diagnostic and Clinical Relevance

Smeenk, R.; Westgeest, Toon; Swaak, Tom J. G.

doi:10.3109/03009748509102067

Cited by 23 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most striking feature of rheumatic diseases, and of SLE in particular, is the large variety of induced clinical manifestations and the wide spectrum of autoantibodies found to react with different constituents of normal cells. The antigenic targets of autoantibodies found in SLE include a number of nuclear components (DNA, RNA, histones, histone-DNA complexes, ribonucleoproteins, nuclear enzymes), cytoplasmic components, and components ofthe cell surface (1)(2)(3)(4)(5)(6)(7). The basic question of whether the autoimmune response results from an unusual presentation of certain antigens or from an abnormality or alteration of the immune system itself is still a matter of controversy.…”

Section: Introductionmentioning

confidence: 99%

Presence of antibodies to ubiquitin during the autoimmune response associated with systemic lupus erythematosus.

Muller

Briand

Regenmortel

1988

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Sera from patients with systemic lupus erythematosus (SLE) were shown to react with both ubiquitin and a synthetic fragment of it (residues 22-45) in an ELISA and with ubiquitin in immunoblotting experiments. Close to 80% of lupus patients possessed ubiquitin antibodies, whereas only 55% of them possessed native DNA antibodies, a marker of SLE. Less than 16% of patients with other rheumatic autoimmune diseases possessed antibodies to ubiquitin. Our results indicate that the combined measurement of antibodies to native DNA and to ubiquitin could appreciably increase the detection of SLE cases (up to 85% in our study). It is suggested that ubiquitin, a heat shock protein, could be involved in antibody formation against ubiquitin-protein conjugates present during cellular injury and that this represents a major characteristic of the autoimmune response in SLE.The immunopathology and etiology of systemic lupus erythematosus (SLE) have been intensely investigated in recent years. The most striking feature of rheumatic diseases, and of SLE in particular, is the large variety of induced clinical manifestations and the wide spectrum of autoantibodies found to react with different constituents of normal cells. The antigenic targets of autoantibodies found in SLE include a number of nuclear components (DNA,

show abstract

Section: Introductionmentioning

confidence: 99%

Presence of antibodies to ubiquitin during the autoimmune response associated with systemic lupus erythematosus.

Muller

Briand

Regenmortel

1988

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…60-70'i^> of patients with primary Sjogren's syndrome (pSS). 33% of patients with scleroderma and IVA, of patients with rheumatoid arthritis (RA) [for reviews, see [1][2][3]. Anti-SSA activity is strongly associated with neonatal lupus which is characterized by a transient cutaneous lupus and complete permanent congenital heart block [2.4].…”

Section: Introductionmentioning

confidence: 99%

IgG antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognize different epitopes in 60-kD SSA/Ro protein

Barakat

Meyer

Torterotot

et al. 1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYFive synthetic peptides corresponding to the N-, the C-and a central domain in 60-kD SSA/Ro protein were prepared and tested with sera from 112 patients with systemic lupus erythematosus (SLE). 55 with primary Sjogren's syndrome (pSS) and 29 with rheumatoid arthritis. Among these five fragments, one representing residues 21-41, was recognized by antibodies in 57% ofpSS patients. Interestingly, this peptide was recognized by only a few (^7%) of SLE sera, while 63% of pSS sera and 46% of SLE sera tested in parallel possessed antibodies reacting in ELISA with purified 60-kD SSA protein. The ELISA results were eompared with the pattern of reactivity obtained in immunodiffusion and immunoblotting. The results indicate that the sensitivity of ELISA using peptide 21-41 and pSS sera was in the same range as immunoblotting and higher than immunodifFusion. Thus the peptide 21-41 proved useful for the detection ofanti-SSA antibodies in the sera of patients with pSS. Furthermore, a positive ELISA using peptide 21-41 could be of potential use to discriminate pSS with systemic features from SLE, The fact that peptide 21-41 is recognized by antibodies in pSS but only by very few SLE sera implies that different mechanisms are involved in the anti-SSA immune response in these two autoimmune diseases.

show abstract

“…Heute wird der Test kaum noch angewandt, obwohl keiner der zur Verfügung stehenden Tests ähnlich gute Parameter aufweist. Durch die Veränderung des Krankheitsspektrums war 1982 die Sensitivität bereits auf 73% abgefallen [481, aber auch die Spezifität sank in nachfolgenden Untersuchungen auf unter 30%[41). Antigene weisen in amerikanischen Untersuchungen, so auch in den revidierten Klassifikationskriterien[48), eine Sensitivität von etwa 30% auf, d. h. sie sind noch Akt.Rheumatol.…”

unclassified

Lupus und Butterfly

Schneider¹,

Specker²

1996

Akt Rheumatol

View full text Add to dashboard Cite

Antinuclear Antibody Determination: The Present State of Diagnostic and Clinical Relevance

Cited by 23 publications

References 62 publications

Presence of antibodies to ubiquitin during the autoimmune response associated with systemic lupus erythematosus.

Presence of antibodies to ubiquitin during the autoimmune response associated with systemic lupus erythematosus.

IgG antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognize different epitopes in 60-kD SSA/Ro protein

Lupus und Butterfly

Contact Info

Product

Resources

About